- Home
- AVD vs SKYE Comparison
AVD vs SKYE Comparison
Compare AVD & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVD
- SKYE
- Stock Information
- Founded
- AVD 1969
- SKYE 2012
- Country
- AVD United States
- SKYE United States
- Employees
- AVD N/A
- SKYE N/A
- Industry
- AVD Agricultural Chemicals
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- AVD Industrials
- SKYE Health Care
- Exchange
- AVD Nasdaq
- SKYE Nasdaq
- Market Cap
- AVD 165.8M
- SKYE 94.0M
- IPO Year
- AVD N/A
- SKYE N/A
- Fundamental
- Price
- AVD $4.80
- SKYE $2.73
- Analyst Decision
- AVD Strong Buy
- SKYE Buy
- Analyst Count
- AVD 3
- SKYE 6
- Target Price
- AVD $16.67
- SKYE $18.67
- AVG Volume (30 Days)
- AVD 328.5K
- SKYE 167.7K
- Earning Date
- AVD 11-11-2024
- SKYE 02-09-2025
- Dividend Yield
- AVD 1.27%
- SKYE N/A
- EPS Growth
- AVD N/A
- SKYE N/A
- EPS
- AVD N/A
- SKYE N/A
- Revenue
- AVD $553,839,000.00
- SKYE N/A
- Revenue This Year
- AVD N/A
- SKYE N/A
- Revenue Next Year
- AVD $5.31
- SKYE N/A
- P/E Ratio
- AVD N/A
- SKYE N/A
- Revenue Growth
- AVD N/A
- SKYE N/A
- 52 Week Low
- AVD $4.26
- SKYE $2.25
- 52 Week High
- AVD $14.28
- SKYE $19.41
- Technical
- Relative Strength Index (RSI)
- AVD 46.81
- SKYE 37.40
- Support Level
- AVD $4.46
- SKYE $2.31
- Resistance Level
- AVD $5.01
- SKYE $3.04
- Average True Range (ATR)
- AVD 0.24
- SKYE 0.30
- MACD
- AVD 0.06
- SKYE 0.07
- Stochastic Oscillator
- AVD 72.00
- SKYE 44.68
About AVD American Vanguard Corporation ($0.10 Par Value)
American Vanguard Corp is a United States-based diversified specialty and agricultural products company. It manufactures and formulates chemicals for crops, turf and ornamental plants, and human and animal health protection. These chemicals include insecticides, fungicides, herbicides, molluscicides, growth regulators, and soil fumigants, which are marketed in liquid, powder, and granular forms.
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.